Full Press Release Details
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances.
IRD
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Key Takeaway: Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy